Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [cardiology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

6 papers

TDX-2026-00025

Perioperative Dual Antiplatelet Therapy Management for Unprotected Left Main Coronary Artery Stenting Patients Requiring Elective Non-Cardiac Surgery: A Consensus-Based Approach

Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) require dual antiplatelet therapy (DAPT) to prevent stent thrombosis, a potentially catastrophic event. For unprotected left main coronary artery (ULMCA) PCI, guideline-recommended DAPT duration is typically 12 months. However, the need for elective non-cardiac surgery within this period presents a significant clinical dilemma, balancing the high risk of stent thrombosis if DAPT is prematurely discontinued against the increased bleeding risk during surgery if antiplatelets are continued. This paper synthesizes expert opinions from a clinical Q&A platform regarding the optimal management of a 71-year-old male who underwent ULMCA PCI with a Synergy everolimus-eluting stent 5 months prior and now requires an elective right hemicolectomy for well-differentiated adenocarcinoma. The consensus emphasizes delaying surgery to at least 9 months post-PCI if oncologically feasible. If surgery cannot be delayed, a bridging strategy with intravenous cangrelor is recommended, alongside aspirin continuation, meticulous perioperative monitoring, and a multidisciplinary team approach involving cardiology, oncology, surgery, and anesthesiology. This expert consensus highlights the critical need for individualized risk assessment, shared decision-making, and adherence to established protocols while acknowledging the limitations of current evidence specifically for ULMCA PCI in this high-risk scenario.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
3 contributors 118 votes 9 Apr 2026

TDX-2026-00019

Management of Right Ventricular Dysfunction and Weaning Protocols for Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 Acute Respiratory Distress Syndrome: A Clinical Consensus Initiative

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) provides crucial life support for severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19. Weaning from VV-ECMO presents complex challenges, particularly concerning persistent right ventricular (RV) dysfunction, which can complicate decannulation decisions. This paper synthesizes expert clinical perspectives on VV-ECMO weaning criteria, focusing on RV assessment, sweep gas trial protocols, and the utility of inhaled pulmonary vasodilators. Utilizing a community peer-review platform, two critical care physicians provided detailed protocols and insights, which were subsequently validated by 84 peer votes. Key findings indicate a pragmatic approach to RV dysfunction, where mild residual impairment may be acceptable if gas exchange and hemodynamic stability are maintained. Staged sweep gas trials, extending up to 6 hours, are advocated, with continuous monitoring of respiratory mechanics, gas exchange, and hemodynamic parameters. The use of inhaled iloprost as a bridge therapy for residual pulmonary hypertension during decannulation was also explored. This initiative highlights the variability in current clinical practice and provides a consensus-driven framework to guide VV-ECMO weaning in patients with COVID-19 ARDS and RV dysfunction, emphasizing individualized patient assessment and a multidisciplinary approach.

2 contributors 84 votes 9 Apr 2026

TDX-2026-00018

Immune Checkpoint Inhibitor Rechallenge After Grade 3 Myocarditis in Metastatic Melanoma: A Community Peer-Reviewed Clinical Consensus and Management Framework

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet they are associated with immune-related adverse events (irAEs), including potentially fatal myocarditis. Current guidelines universally recommend permanent discontinuation of ICIs following grade 3 or 4 myocarditis. This consensus paper addresses the critical clinical dilemma of managing progressive metastatic melanoma in a patient who achieved an excellent initial response to pembrolizumab but subsequently developed grade 3 myocarditis, which fully resolved. Utilizing a community peer-review platform involving two expert oncologists and 91 peer votes, a nuanced framework for considering ICI rechallenge was developed. The framework emphasizes stringent criteria, including complete resolution of myocarditis, lack of alternative effective therapies, and life-threatening cancer with prior ICI response, alongside comprehensive patient counseling and intensive cardio-oncology monitoring. Strategies discussed include switching to anti-CTLA4 monotherapy, reduced-dose anti-PD1 rechallenge, and the potential role of prophylactic abatacept or pre-rechallenge endomyocardial biopsy. While acknowledging the significant risks, including a reported 30-60% recurrence rate of myocarditis, the consensus highlights that in highly selected cases with limited alternatives, a carefully managed rechallenge may be considered under strict multidisciplinary oversight. This paper provides an evidence-informed approach to navigate this complex clinical scenario, balancing oncologic benefit with critical cardiac safety.

2 contributors 91 votes 9 Apr 2026

TDX-2026-00005

Interpreting Elevated Cardiac Troponin in Chronic Kidney Disease: An Evidence-Based Framework from Community Peer Consensus

Background: The interpretation of elevated cardiac troponin levels in patients with chronic kidney disease (CKD) presents a significant diagnostic challenge in acute care settings. CKD patients frequently exhibit chronically elevated baseline troponin, complicating the differentiation between acute myocardial infarction (AMI), demand ischemia, and non-ischemic myocardial injury. This ambiguity often leads to diagnostic delays or inappropriate interventions, particularly in the context of atypical symptoms and a desire for early discharge. Methods: This consensus paper synthesizes expert opinions and clinical insights from a peer-reviewed discussion involving four verified physicians (emergency medicine, cardiology, nephrology, internal medicine) on the tachyDx platform, which garnered 73 community peer votes. The methodology involved structured responses to a clinical dilemma, followed by expert review and synthesis. Results: Key findings include the utility of an absolute delta troponin rise of ≥0.05 ng/mL over 3-6 hours, integrated with clinical context, to warrant urgent cardiac evaluation. High-sensitivity troponin assays were deemed more useful in CKD when serial measurements and CKD-specific cutoffs are applied. CT coronary angiography serves as a valuable gatekeeper for intermediate-risk patients with adequate renal function (eGFR ≥30 mL/min/1.73m²), while pharmacologic stress testing is preferred for advanced CKD. A structured risk stratification approach was developed, emphasizing the integration of ECG, hemodynamic status, and symptomology. Conclusions: An integrated, multi-modal approach, combining serial high-sensitivity troponin measurements with an absolute delta threshold, careful clinical assessment, and judicious use of advanced imaging, is crucial for accurate risk stratification and management of CKD patients with suspected acute coronary syndromes. Effective patient communication regarding diagnostic timelines is also vital.

4 contributors 73 votes 6 Apr 2026

TDX-2026-00002

Optimizing SGLT2 Inhibitor Initiation in Acute Decompensated Heart Failure with Reduced Ejection Fraction: A Multi-Specialty Clinical Consensus

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated significant benefits in chronic heart failure with reduced ejection fraction (HFrEF) and, more recently, in acute decompensated heart failure (ADHF). However, practical guidance regarding their initiation during ADHF hospitalization, particularly in patients with concomitant renal impairment, remains a subject of clinical debate. This consensus paper synthesizes expert opinion on critical aspects of SGLT2 inhibitor use in this acute setting. Methods: This study utilized a community peer-review methodology facilitated by the tachyDx platform. A clinical scenario involving a 68-year-old female with ADHF-HFrEF and an eGFR of 32 mL/min/1.73m² was presented to a panel of four verified physicians (Cardiology, Nephrology, Internal Medicine). Their responses, addressing specific questions on eGFR thresholds, renal monitoring, AKI risk, and agent selection, were subjected to peer voting by 89 community physicians, establishing a consensus-driven framework. Results: Consensus emerged for SGLT2 inhibitor initiation at eGFR thresholds as low as 20-25 mL/min/1.73m², provided hemodynamic stability and euvolemia are achieved. Renal function monitoring at 48 hours and 7 days post-initiation was recommended, with an expected initial eGFR dip of 3-5 mL/min. The perceived risk of acute kidney injury (AKI) was primarily attributed to volume depletion rather than direct drug effect, necessitating concomitant loop diuretic dose reduction (20-30%). Full-dose initiation was advocated once patients were stable (off vasopressors/inotropes for 24 hours, stable diuretics). Euglycemic diabetic ketoacidosis was identified as a rare but significant concern, particularly in nutritionally compromised patients. Conclusions: This multi-specialty consensus supports the early initiation of SGLT2 inhibitors in hemodynamically stable ADHF-HFrEF patients, even with moderate renal impairment, emphasizing careful volume management and renal monitoring. These findings provide practical, evidence-informed guidance for clinicians navigating the complexities of SGLT2 inhibitor use in the acute care setting.

4 contributors 89 votes 6 Apr 2026

TDX-2026-00001

Evidence-Based Framework for Vasopressor and Inotrope Sequencing in Septic Shock with Concurrent Right Ventricular Failure: A Community Peer-Reviewed Clinical Consensus

Background: Septic shock frequently leads to complex hemodynamic instability, often complicated by acute right ventricular (RV) failure. This co-occurrence significantly increases morbidity and mortality, presenting a therapeutic challenge due to the intricate interplay between systemic vasodilation, elevated pulmonary vascular resistance (PVR), and myocardial dysfunction. Optimal vasopressor and inotropic agent sequencing in this specific clinical scenario remains a subject of ongoing debate and lacks definitive guideline recommendations. Methods: This consensus paper synthesizes expert opinions from a clinical Q&A discussion hosted on a specialized physician peer-review platform. Five verified critical care and cardiology specialists contributed to the discussion, which garnered 130 community peer votes. The methodology involved a structured analysis of proposed treatment algorithms, evaluation of supporting evidence, and identification of key monitoring parameters to establish a practical, stepwise approach. Results: A consensus emerged advocating for early initiation of vasopressin (0.03-0.04 U/min) as an adjunct to norepinephrine, prioritizing its favorable PVR profile over further norepinephrine escalation. Low-dose dobutamine (2.5-5 mcg/kg/min) was recommended for targeted RV inotropic support once mean arterial pressure was stabilized. In cases of refractory RV dysfunction, inhaled epoprostenol (20-50 ng/kg/min) was endorsed for selective pulmonary vasodilation. Agents such as phenylephrine and milrinone were strongly discouraged due to their potential to exacerbate RV afterload or systemic hypotension, respectively. Conclusions: This consensus provides a structured, evidence-informed approach to vasopressor and inotrope sequencing in septic shock with concurrent RV failure. The recommendations emphasize a physiologically guided strategy, prioritizing agents that minimize RV afterload while supporting contractility, alongside vigilant hemodynamic and echocardiographic monitoring. This framework aims to guide clinicians in managing this high-risk patient population.

5 contributors 130 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1